Page 2 - Nasdaq Iron News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq iron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Iron Today - Breaking & Trending Today

Disc Medicine's (IRON) "Outperform" Rating Reiterated at Raymond James

Raymond James restated their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report sent to investors on Monday, MarketBeat Ratings reports. Raymond James currently has a $40.00 target price on the stock, down from their prior target price of $75.00. IRON has been the subject of several other reports. […] ....

Kevin Bitterman , Raymond James , Steward Partners Investment Advisory , Securities Exchange Commission , Ameritas Investment Partners Inc , Venture Fund Xlp Atlas , Cantor Fitzgerald , Disc Medicine Inc , Morgan Stanley , Tower Research Capital , Disc Medicine Company Profile , Disc Medicine , Free Report , Marketbeat Ratings , Moderate Buy , Get Free Report , Director Kevin Bitterman , Venture Fund , Exchange Commission , Partners Investment Advisory , Investment Partners , Research Capital , Disc Medicine Daily , Nasdaq Iron , Reiterated Rating ,

Disc Medicine (NASDAQ:IRON) PT Lowered to $71.00 at Stifel Nicolaus

Disc Medicine (NASDAQ:IRON – Get Free Report) had its price objective decreased by research analysts at Stifel Nicolaus from $104.00 to $71.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 107.54% from the stock’s […] ....

Raymond James , Stifel Nicolau , Kevin Bitterman , Stifel Nicolaus , Venture Fund Xlp Atlas , Morgan Stanley , Millennium Management , Citigroup Inc , Disc Medicine Company Profile , Disc Medicine Inc , Geode Capital Management , Securities Exchange Commission , Renaissance Technologies , Disc Medicine , Get Free Report , Director Kevin Bitterman , Exchange Commission , Venture Fund , Capital Management , Point Capital Management , Disc Medicine Daily , Nasdaq Iron , Lower Price Target ,

Morgan Stanley Trims Disc Medicine (NASDAQ:IRON) Target Price to $40.00

Disc Medicine (NASDAQ:IRON – Get Free Report) had its price objective cut by Morgan Stanley from $75.00 to $40.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 26.78% from the stock’s previous close. A […] ....

Kevin Bitterman , Stifel Nicolaus , Raymond James , Renaissance Technologies , Citigroup Inc , Venture Fund Xlp Atlas , Geode Capital Management , Securities Exchange Commission , Disc Medicine Inc , Morgan Stanley , Millennium Management , Disc Medicine , Get Free Report , Medicine Trading Down , Director Kevin Bitterman , Exchange Commission , Venture Fund , Capital Management , Point Capital Management , Disc Medicine Daily , Nasdaq Iron , Lower Price Target ,

Equities Analysts Set Expectations for Disc Medicine, Inc.'s Q1 2024 Earnings (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON – Free Report) – Investment analysts at Leerink Partnrs reduced their Q1 2024 EPS estimates for shares of Disc Medicine in a note issued to investors on Thursday, March 21st. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($1.10) per share for the quarter, down from their […] ....

New Zealand General , New Zealand , Kevin Bitterman , Leerink Partnrs , Venture Fund Xlp Atlas , Vanguard Group Inc , Cantor Fitzgerald , Wellington Management Group , Virtu Financial , Morgan Stanley , Goldman Sachs Group Inc , Financial Services Group Inc , Securities Exchange Commission , Disc Medicine Inc , Disc Medicine Company Profile , Disc Medicine , Free Report , Medicine Stock Down , Venture Fund , Exchange Commission , Director Kevin Bitterman , Services Group , Management Group , Sachs Group , Get Free Report , Disc Medicine Daily ,

Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of "Buy" from Brokerages

Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) has received a consensus recommendation of “Buy” from the ten research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. […] ....

Joanne Bryce , Renaissance Technologies , Geode Capital Management , Millennium Management , Cantor Fitzgerald , Orbimed Advisors Llc , Citigroup Inc , Morgan Stanley , Securities Exchange Commission , Disc Medicine Inc , Disc Medicine , Get Free Report , Exchange Commission , Director Orbimed Advisors Llc , Capital Management , Point Capital Management , Get Free , Disc Medicine Daily , Nasdaq Iron ,